1. Home
  2. IRD vs CLPS Comparison

IRD vs CLPS Comparison

Compare IRD & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • CLPS
  • Stock Information
  • Founded
  • IRD 2018
  • CLPS 2005
  • Country
  • IRD United States
  • CLPS Hong Kong
  • Employees
  • IRD N/A
  • CLPS N/A
  • Industry
  • IRD
  • CLPS Computer Software: Prepackaged Software
  • Sector
  • IRD
  • CLPS Technology
  • Exchange
  • IRD NYSE
  • CLPS Nasdaq
  • Market Cap
  • IRD 36.0M
  • CLPS 35.1M
  • IPO Year
  • IRD N/A
  • CLPS 2018
  • Fundamental
  • Price
  • IRD $1.13
  • CLPS $1.33
  • Analyst Decision
  • IRD Strong Buy
  • CLPS
  • Analyst Count
  • IRD 1
  • CLPS 0
  • Target Price
  • IRD $8.00
  • CLPS N/A
  • AVG Volume (30 Days)
  • IRD 144.3K
  • CLPS 21.5K
  • Earning Date
  • IRD 02-24-2025
  • CLPS 03-04-2025
  • Dividend Yield
  • IRD N/A
  • CLPS 9.91%
  • EPS Growth
  • IRD N/A
  • CLPS N/A
  • EPS
  • IRD N/A
  • CLPS N/A
  • Revenue
  • IRD $8,381,000.00
  • CLPS $142,812,726.00
  • Revenue This Year
  • IRD N/A
  • CLPS N/A
  • Revenue Next Year
  • IRD $29.37
  • CLPS N/A
  • P/E Ratio
  • IRD N/A
  • CLPS N/A
  • Revenue Growth
  • IRD N/A
  • CLPS N/A
  • 52 Week Low
  • IRD $0.81
  • CLPS $0.68
  • 52 Week High
  • IRD $2.71
  • CLPS $1.70
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • CLPS 62.50
  • Support Level
  • IRD N/A
  • CLPS $1.19
  • Resistance Level
  • IRD N/A
  • CLPS $1.36
  • Average True Range (ATR)
  • IRD 0.00
  • CLPS 0.07
  • MACD
  • IRD 0.00
  • CLPS 0.00
  • Stochastic Oscillator
  • IRD 0.00
  • CLPS 82.46

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About CLPS CLPS Incorporation

CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.

Share on Social Networks: